CANF — Can Fite Biopharma Balance Sheet
0.000.00%
Last trade - 00:00- $14.60m
- $9.77m
- $0.67m
Annual balance sheet for Can Fite Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 8.34 | 4.63 | 2.99 | 4.3 | 4.83 |
| Net Total Receivables | 0.018 | 0.048 | 0.047 | 0.078 | 0.077 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 9.4 | 20.1 | 9.16 | 9.91 | 8.98 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.123 | 0.185 | 0.126 | 0.081 | 0.138 |
| Long Term Notes Receivable | |||||
| Total Assets | 9.52 | 20.3 | 9.28 | 9.99 | 9.12 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.27 | 2.73 | 2.5 | 2.02 | 2.05 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.45 | 5.87 | 4.81 | 3.75 | 3.68 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 6.07 | 14.4 | 4.47 | 6.24 | 5.44 |
| Total Liabilities & Shareholders' Equity | 9.52 | 20.3 | 9.28 | 9.99 | 9.12 |
| Total Common Shares Outstanding |